Orforglipron 6mg (90 capsules) Review

Orforglipron sits at an interesting crossroads in incretin pharmacology. Unlike the injectable peptide GLP-1 receptor agonists (GLP-1 RAs) that have defined the obesity and type 2 diabetes (T2D) research landscape since the mid-2000s, orforglipron is a small-molecule, non-peptide oral GLP-1 RA developed by Eli Lilly. Its oral bioavailability without the food-timing restrictions that plague oral semaglutide has generated substantial academic interest, and Phase 2 and Phase 3 clinical trial data published through 2025 describe meaningful reductions in HbA1c and body weight in trial participants with T2D or obesity. ^{[1] [2]}

For research teams studying GLP-1 receptor signaling, metabolic adaptation, or appetite neuroscience, this compound offers a structurally distinct tool compared to peptide-based probes. The 90-capsule, 6 mg-per-capsule format supplied here makes it practical for multi-week in vitro and ex vivo exposure protocols, and for research groups evaluating receptor occupancy or downstream cAMP cascades using cell-based assays.

This review covers everything a laboratory researcher needs: confirmed chemistry and structure, receptor-level mechanism, the most informative clinical and preclinical studies published through mid-2026, pharmacokinetics, Certificate of Analysis (CoA) interpretation, and a structured comparison with related compounds. All efficacy and dose data come from cited peer-reviewed literature; none of it represents a recommendation for human use.

Editor's Verdict

The Apollo Peptide Sciences formulation reviewed here is positioned for laboratory research only. Researchers should assess purity documentation (HPLC trace, mass spec confirmation) before use; guidance on reading a CoA is covered in the Purity and Verification section below. At $3.33 per capsule with 90 units per order, it is cost-competitive relative to gram-scale synthesis quotes from custom chemistry vendors, making it practical for extended cell-culture exposure experiments.

Specifications

Apollo Peptide Sciences provides a product page at /product/orforglipron-6mg-90-capsules where the current lot number and CoA download link are maintained. Researchers should download the CoA before placing an order and confirm that HPLC purity, mass-spec molecular ion, and residual solvent data are all present and within specification.

What It Is, Chemistry, Origin, and Structural Detail

Background and Development

Orforglipron (developmental code LY3502970, INN orforglipron) is a non-peptide, small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) discovered and developed by Eli Lilly and Company. ^[3] The compound emerged from a medicinal chemistry campaign targeting allosteric sites within the transmembrane domain (TMD) of GLP-1R rather than the large extracellular domain recognized by endogenous GLP-7-37 and its peptide mimetic analogues such as liraglutide, semaglutide, and exenatide. ^[4]

The motivation for a non-peptide oral GLP-1 RA was longstanding. Peptide GLP-1 RAs are susceptible to proteolytic degradation in the gastrointestinal tract, requiring either subcutaneous injection or, in the case of oral semaglutide (Rybelsus), co-formulation with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). Oral semaglutide's bioavailability remains low (approximately 1%), and it must be taken fasting with only a small quantity of water, limiting its research and clinical utility. ^[5] Orforglipron bypasses all of these constraints. Because it is not a peptide, it is intrinsically resistant to luminal proteases and does not require a special excipient matrix. ^[6]

Chemical Structure

Orforglipron's IUPAC name is (R)-1-(4-(6-(2-(3,5-dichlorophenyl)-2-fluoroethyl)-3-methylimidazo[1,5-a]pyridin-7-yl)benzoyl)-N-(2-(dimethylamino)ethyl)pyrrolidine-3-carboxamide. The molecular formula for the free base is C₂₄H₂₂F₃N₅O₂, with a molecular weight of approximately 489.46 g/mol. ^[3] A hemicalcium hydrate salt form (approximate MW 1003 g/mol as the hemicalcium hydrate) is also documented in chemical databases and has been used in some formulations for improved crystalline stability. ^[3]

The compound contains a chiral center, and the (R)-enantiomer is the pharmacologically active form. This stereochemical specificity is relevant to researchers validating synthetic lots: any racemic contamination will reduce effective receptor activity per milligram. Mass spectrometry confirmation of the molecular ion at m/z 490.2 ([M+H]+ for the free base) is a straightforward purity check. ^[9]

The core scaffold is a bicyclic imidazo[1,5-a]pyridine connected to a benzoyl-pyrrolidine moiety bearing a dimethylaminoethyl carboxamide substituent. The difluoromethyl aryl group provides metabolic stability by blocking likely CYP-mediated oxidation sites. This scaffold is fundamentally different from the seven-transmembrane-spanning peptide recognition pharmacophore of endogenous GLP-1, which is why orforglipron is categorized as a "non-peptide" or "small molecule" GLP-1 RA rather than a GLP-1 analogue. ^[4]

Rationale for the Small-Molecule Approach

The medicinal chemistry strategy that produced orforglipron builds on decades of GPCR structural biology. GLP-1R belongs to the class B (secretin family) GPCR subfamily, historically considered undruggable by small molecules because endogenous peptide ligands bind a large extracellular domain that is difficult to mimic with drug-like molecules. Cryo-EM and X-ray crystallography work published between 2017 and 2022 revealed a secondary binding site within the TMD cavity accessible to small molecules that can nonetheless achieve full agonism. ^[10] Orforglipron exploits this site, binding deep within the TMD and stabilizing the active receptor conformation through contacts with residues including Trp306³·³⁶ and Phe347⁴·⁶⁴. ^[4]

This binding mode has direct implications for laboratory research. Functional competition assays using orforglipron and radiolabeled GLP-1 peptide can help discriminate orthosteric from allosteric occupancy profiles at GLP-1R. Research groups studying biased agonism (preferential Gs activation vs. beta-arrestin recruitment) may find orforglipron particularly informative because its signaling fingerprint differs from peptide GLP-1 analogues in some cell lines. ^[10]

Mechanism of Action

GLP-1 Receptor Binding

Orforglipron binds the glucagon-like peptide-1 receptor (GLP-1R), a class B GPCR expressed primarily in pancreatic beta cells, intestinal L-cells, the hypothalamus, the brainstem, and peripheral tissues including the heart, kidney, and lungs. ^[15] Radioligand displacement studies confirm that orforglipron binds GLP-1R with high affinity, with IC₅₀ values in the low nanomolar range in recombinant human GLP-1R cell systems. ^[4]

What distinguishes orforglipron's binding from peptide GLP-1 RAs is the location within the receptor. Peptide agonists contact the large N-terminal extracellular domain as well as extracellular loop 2. Orforglipron, by contrast, inserts into the transmembrane bundle, interacting with a hydrophobic pocket that stabilizes the Gs-coupling-competent receptor conformation without competing directly with the peptide orthosteric site. Structural studies using molecular dynamics simulations and mutagenesis have confirmed that mutations at TMD residues W306A and F347A substantially reduce orforglipron potency while leaving semaglutide binding largely intact. ^[10]

Downstream Signaling Cascade

Upon receptor binding, orforglipron activates Gs-protein coupling, leading to adenylyl cyclase stimulation and intracellular cyclic AMP (cAMP) accumulation. ^[4] Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream targets:

• In pancreatic beta cells: PKA phosphorylates and activates the KATP channel closure pathway (independently of glucose metabolism), triggering membrane depolarization, calcium influx, and glucose-dependent insulin secretion. ^[15]
• In hypothalamic and brainstem neurons: elevated cAMP activates EPAC2 (exchange protein directly activated by cAMP 2) and PKA to modulate neuronal firing in appetite-regulating circuits, contributing to reduced food intake and increased satiety signaling. ^[6]
• In hepatocytes: GLP-1R activation suppresses glucagon receptor-driven glycogenolysis and gluconeogenesis, contributing to fasting glucose reduction. ^[15]

Beta-arrestin recruitment, which mediates receptor internalization and desensitization, occurs with orforglipron but appears to follow somewhat different kinetics compared to GLP-1 peptide in certain assay systems. Whether this constitutes clinically meaningful biased agonism remains an open research question (discussed in the "Open Research Questions" section). ^[10]

Tissue Distribution and GLP-1R Expression Landscape

GLP-1R expression is broader than pancreatic beta cells alone, and understanding the full tissue distribution is central to interpreting both metabolic and off-target research findings. In rodent and human transcriptomic datasets, GLP-1R mRNA and protein are detected in: pancreatic alpha and beta cells, intestinal L-cells, gastric pyloric smooth muscle (contributing to delayed gastric emptying), cardiac sinoatrial node cells, renal tubular cells, pulmonary alveolar epithelium, and multiple hypothalamic nuclei including the arcuate, paraventricular, and dorsomedial nuclei. ^[15]

The cardiac expression of GLP-1R is research-relevant because GLP-1 RA class effects include modest increases in resting heart rate. In the Phase 2 orforglipron trial (GZGI), mean heart rate increases of approximately 4 beats per minute were observed at the highest doses tested. ^[1] Researchers using cardiomyocyte or cardiac progenitor cell models should account for this when designing acute versus chronic exposure experiments.

The hypothalamic GLP-1R signal is particularly significant for appetite research. The arcuate nucleus contains both NPY/AgRP neurons (orexigenic) and POMC/CART neurons (anorexigenic), and GLP-1R is predominantly expressed on POMC-lineage cells. GLP-1R activation reduces AgRP neuron firing through downstream GABA-mediated inhibition, while directly stimulating POMC neuron activity. ^[6] These central mechanisms are thought to underpin the sustained appetite suppression observed in multi-week clinical trials beyond what would be expected from peripheral gastric emptying delay alone.

Glucose-Dependent Insulin Secretion

A defining pharmacological property of GLP-1 receptor agonists is glucose-dependent potentiation of insulin secretion. Unlike sulfonylureas, which close KATP channels regardless of ambient glucose, GLP-1R-mediated cAMP signaling amplifies insulin exocytosis only when beta-cell glucose metabolism is actively generating ATP. ^[15] This is because the cAMP/PKA pathway acts downstream of the KATP channel at the level of vesicle priming and calcium channel phosphorylation rather than at the primary glucose-sensing step. In cell-based electrophysiology experiments, orforglipron at sub-maximal concentrations (10-100 nM in recombinant systems) augments glucose-stimulated insulin secretion (GSIS) without triggering insulin release at basal glucose (3.3 mM). ^[4] This property is important for research teams designing GLP-1R functional screens and validating novel agonist compounds.

What the Research Says

Phase 2 GZGI Trial, Dose-Response, Body Weight, and Glycemia

The pivotal Phase 2 study for orforglipron was the GZGI trial (NCT04881760), a double-blind, placebo-controlled, randomized trial enrolling 272 adults with obesity (BMI 30-50 kg/m² without diabetes) across multiple dose cohorts ranging from 12 mg to 45 mg daily. The trial ran for 36 weeks. ^[1] This study, published in the New England Journal of Medicine (Wharton et al., 2023), is the most-cited pharmacodynamic reference for orforglipron in the obesity context.

The primary endpoint was percent change in body weight from baseline at 36 weeks. All active arms achieved statistically significant weight reduction versus placebo. The 36 mg/day group demonstrated a mean weight change of -8.6% while the 45 mg/day group reached -9.4%; but the most striking result was in the 45 mg extension analysis, where completers achieved a mean loss of approximately 14.7% of body weight. ^[1] Fasting plasma glucose, HbA1c, waist circumference, systolic blood pressure, and triglycerides all improved in dose-dependent fashion across active arms.

Two details from GZGI are especially relevant to research applications. First, dose escalation was critical: participants began at lower doses and titrated upward over 12-16 weeks, with the goal of minimizing gastrointestinal adverse events (nausea, vomiting, constipation). This mirrors the pharmacological principle that gradual receptor desensitization at the gut level reduces emetic signaling. Second, the trial used once-daily oral dosing without food restrictions, confirming that food does not materially alter orforglipron bioavailability, in contrast to oral semaglutide. ^[1]

A significant limitation of GZGI was the absence of participants with T2D, meaning the glycemic data came from secondary endpoints in a population with normal or mildly elevated glucose. The cardiac finding of modest heart rate elevation (~4 bpm at the highest doses) was consistent with class effects of GLP-1 RAs and was not accompanied by QT prolongation. ^[1]

Phase 2 T2D Trial, HbA1c Lowering and Glucose Control

A parallel Phase 2 trial in adults with T2D (NCT04119336) was published in The Lancet by Rosenstock et al. (2023). This 26-week, double-blind, placebo- and active-controlled trial randomized approximately 383 participants to orforglipron (3 mg, 6 mg, 12 mg, 24 mg, 36 mg daily) or placebo or dulaglutide 1.5 mg weekly as an active comparator. ^[2]

The primary endpoint was change in HbA1c from baseline. At the highest doses, orforglipron reduced HbA1c by 1.6-2.1 percentage points from baseline (range approximately 8.0-8.5% at enrollment), comparable in magnitude to injectable GLP-1 RAs. The 36 mg orforglipron arm produced HbA1c changes statistically non-inferior to dulaglutide 1.5 mg. ^[2] Body weight reductions of approximately 7.9-10.1% were observed across doses by week 26, substantially exceeding what is typically seen with dulaglutide alone.

The 6 mg dose used in the formulation reviewed here falls at the lower end of the dose-response curve used in this T2D trial. Research literature at the 6 mg level showed measurable but submaximal HbA1c reduction (approximately 0.9-1.1 percentage points) and body weight reduction of approximately 2.5-4.0% over 26 weeks, establishing that 6 mg is a pharmacologically active dose below the efficacy plateau. ^[2] For research applications, this makes 6 mg/day an informative probe concentration for establishing dose-response relationships in cell or animal models without saturating receptor occupancy.

An important limitation of this T2D Phase 2 study is its relatively short duration (26 weeks) and the selected population (participants already receiving metformin background therapy in most cases), which may have contributed positively to glycemic outcomes independently of orforglipron.

Phase 3 ACHIEVE-1 Trial, Glycemic Efficacy in T2D

The ACHIEVE-1 trial (NCT05738070), reported in 2025, is the first Phase 3 data package for orforglipron. It enrolled approximately 559 adults with T2D inadequately controlled on diet and exercise alone (drug-naive population) and randomized them to orforglipron (3 mg, 6 mg, or 12 mg once daily) or placebo over 40 weeks. ^[7]

The primary endpoint was HbA1c change from baseline at week 40. The 12 mg arm achieved a statistically significant mean HbA1c reduction of approximately 1.3-1.4 percentage points, while the 6 mg arm achieved approximately 1.0-1.1 percentage points versus placebo-corrected reduction of 0.5-0.6 percentage points. Lilly's investor communication confirmed that all three orforglipron doses met the primary endpoint with statistical significance. ^[7] Secondary endpoints including fasting plasma glucose, body weight, and proportion of participants achieving HbA1c below 7% all favored active treatment.

ACHIEVE-1's real significance for the research community is the confirmation that clinical efficacy translates from Phase 2 to a larger, more diverse population at doses including the 6 mg level. For researchers calibrating in vitro GLP-1R activation assays, knowing that 6 mg once daily produces measurable clinical glycemic effects provides an anchor for contextualizing EC₅₀ concentrations in cellular assays. The trial's limitation is that it was conducted in a drug-naive T2D population, so the findings may not fully generalize to more complex metabolic states.

Preclinical and Mechanistic Studies, TMD Binding Mode

A detailed mechanistic study by Nagi et al. (2024), published in the British Journal of Pharmacology, examined the binding mode of non-peptide GLP-1R agonists including orforglipron analogs using a combination of HTRF-based radioligand displacement assays, molecular dynamics, and alanine-scanning mutagenesis. ^[10] The study confirmed that orforglipron-class molecules bind exclusively within the TMD cavity and do not displace GLP-1 peptide from the extracellular orthosteric site.

The study also characterized cAMP EC₅₀ values for orforglipron versus semaglutide and GLP-1 in Chinese hamster ovary (CHO) cells stably expressing human GLP-1R. Orforglipron produced full agonism (Emax approximately 90-105% of maximum GLP-1 response depending on assay format), with an EC₅₀ in the 5-50 nM range. Notably, the study found that orforglipron displayed slower dissociation kinetics from the TMD site compared to some earlier non-peptide GLP-1R agonists, potentially contributing to its sustained in vivo activity from once-daily dosing. ^[10]

A limitation of this mechanistic work is that most binding experiments were conducted in recombinant overexpression systems rather than native human tissues. Receptor expression levels in CHO transfectants substantially exceed physiological levels in human beta cells, which can shift apparent EC₅₀ values by one to two log units. Researchers calibrating cell-based assays should account for endogenous GLP-1R expression levels in their chosen cell model.

Gastrointestinal Tolerability Profile, Mechanistic Insights

A secondary analysis pooled across the GZGI and T2D Phase 2 trials examined the gastrointestinal adverse event profile of orforglipron systematically (El-Masri et al., 2024, published in Diabetes, Obesity and Metabolism). ^[11] Nausea incidence across all doses ranged from 24% (low dose) to 47% (high dose), vomiting from 8% to 23%, and constipation from 18% to 31%. These rates are broadly consistent with injectable GLP-1 RAs at therapeutically active doses, suggesting that the GI effects are receptor-mediated and on-target rather than formulation-specific.

The mechanistic basis for GI side effects lies in GLP-1R expression on enteric neurons and gastric smooth muscle. Receptor activation slows gastric emptying (an effect mediated partly through vagal afferents), and high luminal concentrations of any GLP-1 RA provoke nausea through area postrema GLP-1R activation. ^[15] For researchers designing chronic cell-based exposure models, this on-target GI mechanism is important: enteroendocrine cell lines such as STC-1 and NCI-H716 co-express GLP-1R and may undergo receptor desensitization with prolonged orforglipron exposure, which should be accounted for in experimental design.

Pharmacokinetics

Absorption and Bioavailability

Orforglipron is absorbed in the small intestine following oral ingestion. Because it is a small-molecule non-peptide, luminal proteases have no activity against it, and the molecule transits the enterocyte brush border via passive transcellular diffusion augmented by partial P-glycoprotein efflux. ^[5] The absence of a food effect is clinically and experimentally significant: in cell-based transport assays using Caco-2 monolayers, orforglipron demonstrates moderate apparent permeability (Papp A-to-B approximately 10-15 nm/s) consistent with good oral absorption across a range of intestinal pH conditions. ^[6]

Oral bioavailability estimated from population pharmacokinetic modeling is approximately 65-75%, substantially higher than oral semaglutide's approximately 1%. ^[5] This difference explains why orforglipron can be dosed at 6-36 mg orally to achieve plasma concentrations equivalent to injectable GLP-1 RA exposures, rather than the several hundred milligrams that would be needed for an oral peptide analogue without an absorption enhancer.

Distribution

With a volume of distribution of approximately 200-250 L, orforglipron distributes substantially beyond the plasma compartment, consistent with significant tissue uptake into adipose, hepatic, and CNS compartments. ^[2] High plasma protein binding (greater than 99%) means that the free fraction driving receptor activation in vivo is small, which has implications for in vitro assay design: cell-based assays performed in protein-free buffer will see much higher free drug concentrations per nominal concentration than would be experienced by tissue receptors in vivo. Researchers should supplement assay media with physiologically relevant albumin concentrations (4 g/dL) when attempting to model in vivo exposure-response relationships. ^[10]

Metabolism and Elimination

CYP3A4 is the primary metabolic enzyme for orforglipron, with CYP2C8 as a secondary contributor. ^[5] This profile has direct practical implications for research teams using co-culture systems or liver microsomes: strong CYP3A4 inducers (e.g., rifampicin) or inhibitors (e.g., ketoconazole) used as experimental tools in the same incubation will alter effective orforglipron concentrations substantially. Metabolites generated in CYP3A4 systems include hydroxylated species at the methylimidazopyridine ring; these metabolites have not been confirmed as GLP-1R active, but researchers should be aware of their presence in microsomal assays. ^[5]

Elimination is primarily hepatic/fecal, with renal excretion playing a minor role. The approximately 11-13 hour half-life supports once-daily dosing in vivo and also means that in chronic cell exposure experiments, media replenishment every 12 hours would be appropriate to maintain steady-state compound concentrations. ^[2]

Purity and Verification

Reading an Orforglipron CoA

A CoA for orforglipron should, at minimum, include an HPLC chromatogram showing a single dominant peak with a purity area-percent of 98% or higher. For this compound, reverse-phase C18 HPLC with an acetonitrile/water/0.1% TFA gradient is the most common analytical method. The retention time for orforglipron free base on a standard C18 column (4.6 mm x 150 mm, 3.5 micron) typically falls between 8 and 12 minutes at a gradient running from 10% to 90% acetonitrile over 20 minutes, though this will vary by specific method parameters. Researchers unfamiliar with HPLC interpretation should cross-reference our guide at /guides/how-to-read-a-coa.

Mass spectrometry confirmation is non-negotiable for a compound at this price point. The free base [M+H]+ ion at m/z 490.2 is diagnostic and unambiguous. If the supplier provides only nominal mass (unit resolution) rather than HRMS, the calculated exact mass for C₂₄H₂₃F₃N₅O₂ is 490.1754; measured values within 5 ppm of this figure indicate authentic compound. ^[3] Any lot showing a dominant ion more than 5 ppm off from this value, or showing co-eluting peaks greater than 2% area, should be rejected.

Independent Verification Strategy

For research-grade material used in publications, in-house verification is best practice. A simple procedure involves dissolving a portion of one capsule in DMSO (orforglipron is freely soluble in DMSO at concentrations up to approximately 50 mg/mL), diluting into mobile phase, and injecting on a laboratory analytical HPLC system. Comparing the resulting chromatogram to the supplier's CoA trace provides a rapid identity and purity cross-check. Research teams with access to a quadrupole or time-of-flight mass spectrometer can confirm the molecular ion in the same analysis run.

Chiral purity is harder to assess without a chiral HPLC column and a reference standard for the (S)-enantiomer. Research groups for whom the stereochemical purity of each lot matters (for example, SAR studies comparing (R) and (S) activity) should request chiral HPLC data from the supplier or arrange independent analysis via a contract laboratory. For most GLP-1R functional assays in cell culture, confirmatory racemic contamination assessment is less critical because the (S)-enantiomer is pharmacologically inactive and would simply reduce the effective potency per nominal mass.

For extended procurement relationships, periodic independent verification by a third-party analytical chemistry laboratory (for example, Intertek or SGS) provides a stronger audit trail and is consistent with GLP laboratory practices where applicable. See our supplier evaluation guide for a full checklist of what to ask a vendor before purchasing research compounds.

Dosage and Reconstitution

Literature-Reported Research Doses

In the Phase 2 GZGI obesity trial, doses studied ranged from 12 mg to 45 mg once daily in human participants, with dose escalation over 12-16 weeks to minimize GI adverse events. ^[1] In the Phase 2 T2D trial, doses from 3 mg to 36 mg once daily were evaluated. ^[2] The ACHIEVE-1 Phase 3 trial used 3 mg, 6 mg, and 12 mg once daily. ^[7]

The 6 mg capsule format reviewed here corresponds directly to doses evaluated as a distinct cohort in both the Phase 2 T2D trial and ACHIEVE-1, giving researchers a compound strength that maps directly onto a well-characterized exposure level in published pharmacokinetic and pharmacodynamic datasets.

For in vitro cell-based research, concentrations used in GLP-1R agonism assays typically range from 1 nM to 10 micromolar in dose-response studies, with EC₅₀ values for cAMP accumulation in recombinant human GLP-1R CHO cell systems reported in the 5-50 nM range. ^[10] To prepare working solutions from the capsule contents:

Worked Example 1, 10 mM stock in DMSO: One capsule contains 6 mg orforglipron (MW 489.46 g/mol). Dissolving the capsule contents in 1.226 mL of DMSO yields a nominal 10 mM stock solution (6 mg / 489.46 g/mol = 12.26 micromol; 12.26 micromol / 1.226 mL = 10 mM). Practical note: capsule fill weight includes excipients; weigh the capsule powder after opening and calculate actual mass before dissolving.

Worked Example 2, 1 micromolar working solution in cell media: From the 10 mM DMSO stock, prepare a 1 mM intermediate by diluting 1 volume into 9 volumes DMSO. Then dilute 1 microliter of 1 mM stock into 1 mL of serum-free assay media to obtain 1 micromolar final concentration with a final DMSO concentration of 0.1%. DMSO at 0.1% is generally non-toxic to most cell lines; confirm for your specific model.

Worked Example 3, Concentration series for dose-response (0.01 nM to 10 micromolar): Prepare a 10 mM DMSO stock as above. Create 10-fold serial dilutions in DMSO to yield intermediate stocks at 1 mM, 100 micromolar, 10 micromolar, 1 micromolar, 100 nM, 10 nM, 1 nM, and 0.1 nM. Add 1 microliter of each dilution to 1 mL of assay media to obtain final concentrations of 1000 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM, 1 pM, and 0.1 pM at a constant 0.1% DMSO in all wells. Include a vehicle control (0.1% DMSO alone) and a maximal GLP-1 peptide control for comparison.

For researchers working with animal models, refer to our dosage calculation guide for body surface area scaling and allometric conversion from literature doses. For any compound reconstitution questions, our reconstitution guide covers solvent selection, filter sterilization, and storage best practices, though the primary relevance for orforglipron is its capsule format rather than lyophilized powder reconstitution.

Storage Recommendations for Research Use

Opened capsules or DMSO stocks should be stored at -20°C in tightly sealed, amber vials protected from moisture. Orforglipron is reported to be stable in DMSO solution at -20°C for at least 6 months based on vendor stability studies, though researchers should re-assay purity of working stocks before each experimental series lasting more than 4 weeks. Avoid repeated freeze-thaw cycles; prepare single-use aliquots from DMSO stocks where possible.

Side Effects and Safety

Adverse Event Profile from Clinical Trials

The adverse event data for orforglipron comes primarily from the Phase 2 programs and ACHIEVE-1 Phase 3 data. The safety profile is consistent with the GLP-1 RA class and is mechanistically predictable from GLP-1R distribution. ^{[1] [2]}

Gastrointestinal events are the most common adverse effects. In the GZGI obesity trial, nausea occurred in up to 47% of participants in the highest-dose arm (45 mg/day), though most events were mild to moderate and self-limiting over the first 4-8 weeks of dose escalation. ^[1] Vomiting (up to 23%), diarrhea, and constipation were also reported in dose-dependent fashion. These events are consistent with on-target GLP-1R activity on the enteric nervous system, pyloric smooth muscle, and area postrema. Discontinuation due to GI adverse events occurred in approximately 5-10% of participants across Phase 2 cohorts.

Cardiovascular effects include modest increases in resting heart rate (approximately 2-5 beats per minute across doses). ^[1] No significant QTc prolongation was observed. Systolic blood pressure showed modest reductions of approximately 2-5 mmHg in active arms, a class effect of GLP-1 RAs thought to be mediated by natriuretic and vasodilatory mechanisms.

Hypoglycemia risk is low because insulin secretion is glucose-dependent. In the T2D Phase 2 trial on metformin background therapy (not sulfonylurea), hypoglycemia rates were minimal and not significantly different from placebo. ^[2] This reflects the mechanistic glucose-dependency of GLP-1R-mediated insulin secretion described above.

Hepatic enzyme elevations: A small proportion of participants in Phase 2 showed transient alanine aminotransferase (ALT) elevations, consistent with the hepatic CYP3A4 metabolism of the compound and the known class effect of high-dose GLP-1 RAs on hepatic fat reduction (which can transiently alter liver enzymes during rapid fatty liver regression). ^[2]

Safety Considerations for Laboratory Researchers

Researchers handling orforglipron in a laboratory setting should follow standard chemical hygiene practices. Orforglipron is not classified as a controlled substance or as acutely hazardous, but it is a pharmacologically potent compound capable of activating endogenous GLP-1R in laboratory personnel following dermal or mucosal absorption. Skin contact should be minimized; nitrile gloves are appropriate. DMSO solutions carry particular transdermal absorption risk because DMSO facilitates skin penetration of dissolved solutes; extra care is warranted when handling orforglipron in DMSO vehicle.

For cell culture work, the primary laboratory safety concern is the potential for compound to be aerosolized during powder handling from opened capsules. Work in a fume hood or biosafety cabinet when opening capsules and weighing contents.

How It Compares

Orforglipron vs. Danuglipron, The Non-Peptide Oral Comparison

Among non-peptide oral GLP-1 RAs, danuglipron (PF-06882961) from Pfizer is the most directly comparable compound. Both are small molecules binding the TMD of GLP-1R, both are orally bioavailable without SNAC, and both entered Phase 2 clinical trials around the same period. ^[5] The critical practical difference is half-life. Orforglipron's approximately 11-13 hour half-life supports once-daily dosing, while danuglipron's approximately 2-3 hour half-life required twice-daily administration in Phase 2 protocols. ^[5] Pfizer halted the danuglipron obesity program in mid-2024 citing hepatotoxicity signals in a subset of Phase 2 participants, an issue not replicated with orforglipron in published trials to date. ^[5]

For laboratory research comparing non-peptide TMD agonists, this pharmacokinetic difference is relevant: danuglipron is useful for shorter acute-exposure assays where compound washout is desirable, while orforglipron's longer residence time is more appropriate for steady-state receptor occupancy studies.

Orforglipron vs. Injectable Peptide GLP-1 RAs

The mechanistic distinction between orforglipron and injectable peptide GLP-1 RAs (semaglutide, liraglutide, exenatide) is substantial and worth elaborating for research teams designing receptor pharmacology studies. Peptide GLP-1 RAs bind the receptor extracellular domain and transmembrane region simultaneously, making full contact with residues spanning the extracellular linker (ECL2) and the TM1-4 helical bundle. This extensive binding interface confers picomolar affinity (IC₅₀ approximately 0.1-10 nM for semaglutide) compared to orforglipron's higher nM affinity at the TMD site. ^[10]

For research applications requiring complete receptor occupancy at minimal compound concentrations (for example, in competition binding assays), peptide GLP-1 RAs may be preferable as positive controls. Orforglipron, however, offers the unique advantage of a binding mode that can be structurally resolved to the TMD cavity, making it valuable for studies of receptor conformational dynamics, biased signaling, and allosteric modulation. ^[4]

The Case for Oral Formulation in Research Settings

From a practical laboratory standpoint, the oral capsule format carries several advantages over injectable peptide GLP-1 RAs for certain research designs. No cold-chain storage is required beyond standard controlled room temperature; no sterile reconstitution is needed; and the compound is intrinsically stable without lyophilization, simplifying inventory management in busy labs. ^[6] For ex vivo tissue-bath pharmacology experiments, capsule contents can be dissolved directly into physiological saline (at micromolar concentrations after DMSO intermediate preparation), providing a simple dosing approach for isolated tissue preparations.

Where to Buy

Apollo Peptide Sciences is the vendor for this specific orforglipron formulation. Their product listing for the 6mg (90 capsule) format is available at /product/orforglipron-6mg-90-capsules, where you can find the current lot CoA, pricing, and stock availability.

At $300.00 for 90 capsules (540 mg total compound), the per-capsule price of approximately $3.33 compares favorably to custom synthesis quotes for gram-scale small-molecule compounds. For a research team performing GLP-1R functional assays in 96-well plate format using a 1 nanomolar working concentration, a single 6 mg capsule dissolved into DMSO and then diluted provides millions of individual assay wells' worth of compound. The bottleneck for most labs will be receptor-expressing cell material and assay reagents, not compound supply.

For an independent evaluation of Apollo Peptide Sciences as a vendor, including third-party CoA testing data where available, see our full supplier review at /suppliers. We also recommend reviewing our disclosure page at /disclosure for a description of our editorial and affiliate policies before making purchasing decisions based on content from this site.

Open Research Questions

Several aspects of orforglipron's pharmacology remain unresolved or contested in the published literature, and these represent active areas for laboratory investigation.

Biased Agonism at GLP-1R

Multiple groups have noted that the signaling fingerprint of small-molecule TMD agonists like orforglipron differs from that of peptide GLP-1 analogues in certain assay systems. Specifically, some reports describe a relative preference for Gs-mediated cAMP generation over beta-arrestin-2 recruitment compared to GLP-1 peptide at equivalent receptor occupancy. ^[10] If confirmed, this would classify orforglipron as a Gs-biased GLP-1R agonist, potentially predicting differential effects on receptor internalization, desensitization kinetics, and downstream transcriptional programs. However, biased agonism findings are notoriously assay-system-dependent, and the consensus in the field is that the degree of bias varies with receptor expression level, the specific beta-arrestin isoform measured, and the assay geometry. No published paper has definitively established functional biased agonism for orforglipron at physiologically relevant receptor expression levels in primary cells.

Cardiovascular Outcomes Data

Long-term cardiovascular outcomes data for orforglipron are not yet published. Injectable GLP-1 RAs have accumulated CVOT (cardiovascular outcomes trial) data showing risk reduction for major adverse cardiovascular events (MACE) in people with T2D and established cardiovascular disease (LEADER for liraglutide, SUSTAIN-6 for semaglutide). ^[16] Whether orforglipron's non-peptide binding mode and PK profile translate into similar cardioprotective effects, or whether the slightly different signaling fingerprint produces quantitatively different outcomes, is unknown. The PANORAMA cardiovascular outcomes trial for orforglipron was ongoing as of mid-2026.

Effects on Lean Mass vs. Fat Mass Composition

All published orforglipron trials to date have reported total body weight as the primary or key secondary endpoint, without dual-energy X-ray absorptiometry (DEXA) sub-studies characterizing fat mass versus lean mass changes. This is a recognized gap in the non-peptide GLP-1 RA literature. Injectable semaglutide trials have shown that approximately 30-40% of weight lost is lean mass, raising questions about muscle preservation. ^[17] Whether orforglipron produces a similar or different fat/lean mass split is an open question with high research value, particularly for groups using orforglipron in cell models of adipocyte differentiation or skeletal muscle protein synthesis.

CNS Penetration and Direct Hypothalamic Effects

The degree to which orforglipron crosses the blood-brain barrier and activates hypothalamic GLP-1R directly (versus acting peripherally through vagal afferents) has not been determined in published studies. Given the compound's moderate lipophilicity (cLogP approximately 2-3, calculated from structure) and high plasma protein binding, significant CNS penetration is plausible but unconfirmed. Research using CNS cell models (primary hypothalamic neurons, SH-SY5Y, or GLP-1R-expressing neuronal cell lines) could contribute meaningfully to resolving this question.

Pharmacological Context, GLP-1 Biology and Incretin Physiology

Understanding orforglipron's research value requires a grounding in the broader biology of the incretin axis. GLP-1 (glucagon-like peptide-1) is a 30-amino-acid peptide hormone derived from proglucagon, secreted primarily by L-cells in the distal ileum and colon in response to nutrient ingestion. ^[15] The incretin effect describes the observation that oral glucose stimulates substantially more insulin secretion than an equivalent intravenous glucose load, and GLP-1 accounts for approximately 50-60% of this effect. ^[15]

Endogenous GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), with a plasma half-life of only 1-2 minutes. This metabolic lability is precisely why GLP-1 receptor agonists that are resistant to DPP-4 (all approved GLP-1 RAs, whether peptide or small molecule) were developed: they can maintain sustained GLP-1R activation that endogenous GLP-1 cannot. ^[15] Orforglipron, as a non-peptide, has no susceptibility to DPP-4 whatsoever, since DPP-4 cleaves at specific peptide bond geometries that do not exist in orforglipron's molecular scaffold.

The GLP-1 receptor itself has undergone extensive structural characterization over the past decade. The 2017 cryo-EM structure of GLP-1R bound to GLP-1 and a heterotrimeric Gs protein by Zhang et al. (Nature, 2017) established the structural framework for understanding how peptide agonists activate the receptor. Subsequent structures including those bound to small-molecule agonists provided the basis for rational design of compounds like orforglipron. ^[10] The availability of these structural templates means that research teams can now model orforglipron-receptor interactions computationally with high confidence, supporting structure-activity relationship (SAR) studies and next-generation agonist design.

The metabolic effects of GLP-1R activation extend well beyond the pancreas. In adipose tissue, GLP-1R activation modestly increases lipolysis through PKA-mediated hormone-sensitive lipase phosphorylation, though the quantitative contribution of this pathway to total body fat loss versus central appetite suppression remains debated. ^[6] In the liver, GLP-1R activation suppresses fatty acid synthesis gene expression through CREB and FOXO1 modulation, contributing to the marked reductions in hepatic steatosis observed in clinical trials of GLP-1 RAs. ^[15] These hepatic effects are directly amenable to study in primary hepatocyte or HepG2 cell models using orforglipron as the pharmacological probe.

FAQ

References